KRAS and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, resistance to targeted therapy with imatinib, an inhibitor of BCR-ABL used in the treatment of chronic myeloid leukaemia, can arise from a C to T SNV resulting in T315I mutation;8 specific therapeutics have been developed for this mutation.9 Another example is a mutation in KRAS (G12C)10 which is the target of the first KRAS-targeting drug in clinical development.11 Accordingly, technologies to analyse SNPs and SNVs are critical in medical diagnosis, personalized medicine and many other scientific disciplines.